Argitalpenak (65) CARLOS JESUS DUEÑAS GUTIERREZ argitalpenak

2024

  1. Real-life data of immune recovery using bictegravir/emtricitabine/ tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study

    Journal of Antimicrobial Chemotherapy, Vol. 79, Núm. 3, pp. 595-607

2023

  1. Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

    Viruses, Vol. 15, Núm. 2

  2. Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 7, pp. 1658-1666

  3. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

    Viruses, Vol. 15, Núm. 4

  4. Impact of COVID-19 on Adherence to Treatment in Patients with HIV

    Healthcare (Switzerland), Vol. 11, Núm. 9

  5. Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)

    Journal of Clinical Medicine, Vol. 12, Núm. 3

  6. Randomized Controlled Trial Evaluating the Benefit of a Novel Clinical Decision Support System for the Management of COVID-19 Patients in Home Quarantine: A Study Protocol

    International journal of environmental research and public health, Vol. 20, Núm. 3

  7. Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses

    BMC Infectious Diseases, Vol. 23, Núm. 1

2022

  1. A predictive model of immune recovery for DTG + 3TC and DTG + RPV used as switching strategies in HIV+ patients

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 12, pp. 3519-3523

  2. Chronic use of renin–angiotensin–aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis

    Medicina Clinica, Vol. 158, Núm. 7, pp. 315-323

  3. Discovering HIV related information by means of association rules and machine learning

    Scientific Reports, Vol. 12, Núm. 1

  4. Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study

    Medicine (United States), Vol. 101, Núm. 24, pp. E29252

  5. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial

    JAMA Network Open, Vol. 5, Núm. 1

  6. Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection

    AIDS (London, England), Vol. 36, Núm. 15, pp. 2171-2179

  7. Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir

    Drug design, development and therapy, Vol. 16, pp. 827-841

2021

  1. Can the Cytokine Profile According to ABO Blood Groups Be Related to Worse Outcome in COVID-19 Patients? Yes, They Can

    Frontiers in Immunology, Vol. 12

  2. Corticosteroid Pulses for Hospitalized Patients with COVID-19: Effects on Mortality

    Mediators of Inflammation, Vol. 2021

  3. Evaluation of cytokines as robust diagnostic biomarkers for COVID-19 detection

    Journal of Personalized Medicine, Vol. 11, Núm. 7

  4. HGF, IL-1α, and IL-27 are robust biomarkers in early severity stratification of COVID-19 patients

    Journal of Clinical Medicine, Vol. 10, Núm. 9

  5. Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in COVID-19

    Cardiology journal, Vol. 28, Núm. 3, pp. 360-368